Biopharma News : Biopharma and Pharma news from all around the world :
- Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
- Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
- Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology
- Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
- Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC
- Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue
- ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
- Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
- LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions
- HealthWarehouse.com Reports Full Year 2025 Results
- IntraBio Announces Submission of Supplemental New Drug Application for Levacetylleucine for Ataxia-Telangiectasia
- Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
- KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference
- Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration
- Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results
- Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
- FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
- Guardian Pharmacy Services Announces Launch of Underwritten Public Offering of Class A Common Stock
- GE HealthCare completes Intelerad acquisition – accelerating shift to cloud-first enterprise solutions to deliver precision care
- Nia Therapeutics Receives FDA Breakthrough Device Designation for AI-Guided Brain Implant to Treat Memory Loss
- Dyno Therapeutics Launches Dyno Psi-Phi, an Agentic AI Suite for Protein Binder Design, at NVIDIA GTC 2026
- QHP Announces $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals
- Mave Health Raises $2.1M to Launch Focus and Stress Regulation Wearable
- Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift
- Tiny Cargo and Bio-Sourcing Partner to Develop First-of-Its-Kind Oral Monoclonal Antibody Platform Using Goat-Milk Exosomes
- Open Molecular Software Foundation’s OpenFold Consortium Launches Research Fellowship at the University of Washington’s Institute for Protein Design
- Niagen Bioscience to Present at the 38th Annual ROTH Conference
- Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer
- RevnaBio Secures Triple International Laboratory Accreditation to Expand Precision Medicine and Clinical Research Infrastructure in Africa
- KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD
- Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
- Newron to present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
- Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
- MEDICLIN invites you to the 2026 virtual press conference on the financial statements for the year 2025
- Secarna Pharmaceuticals establishes Advisory Board with financial markets expert Jens Holstein and shareholder representative Richard Mark Engelhard
- Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
- Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
- Viromed Medical AG: Anna Heinen appointed to the Supervisory Board
- PolyPeptide strengthens financing structure through expansion of existing credit facility
- DocMorris and Google partner to advance one of Europe’s leading AI-powered digital health platform
- DocMorris achieves 2025 targets – focus on profitability, growth and expansion of digital health platform
- Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
- aap successfully completes MDR certification: All existing products approved according to MDR – market access in the EU and CE-relevant markets secured in the long term
- Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
- Darwin AG launches commercialization of Multi-Cancer Check — a blood test for early detection of 13 types of cancer
- Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets
- Newron announces nominations to its Board of Directors at upcoming Annual General Meeting
- BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
- Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
- Cantourage Group SE publishes preliminary figures for 2025 – Revenue rises to EUR 92.8 million
- Medartis builds on momentum with 16% organic sales growth and core EBITDA margin exceeding 18%
- PolyPeptide publishes invitation to the annual General Meeting 2026
- Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets
- Major Milestone CF PHARMTECH, INC. 2652.HK Announces IND Acceptance for PAH New Drug with a Globally Innovative Improved Mechanism, Marking Another Milestone for Its Precision Drug Delivery Platform
- Chia Tai Enterprises International Proposes Name Change to CPBIO Biotech is the Core Growth Engine: Innovation Fuels Diversified Portfolio
- BIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon
- NVision and Aarhus University Awarded Innovation Fund Denmark Grant to Advance Clinical Translation of Quantum-Enhanced MRI
- BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
- INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia
- HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
- Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
- Akemi Hair Glow Claims Evaluated: 2026 Hair Growth Transparency Report Examines DHT-Blocking Spray Research, “56% Thicker Hair” Data, and Ingredient Research for Women
- IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy
- Financière de Tubize – Annual report 2025
- Garaherb Claims Evaluated: Complete Scientific Investigation of Ingredients’ Effectiveness
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
- Disclosure of a transparency notification from Aberdeen Group plc
- SafeSpace Global Corporation Reports Q2 Fiscal 2026 Financial Results; Company Transitions from Pre-Revenue to Revenue-Generating Stage, Expands Footprint with Nashville Office, and Initiates Steps Toward National Exchange Uplisting
- Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
- Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
- Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors
- BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
- RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
- WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial
- Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
- Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology’s Annual Scientific Session
- Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
- Human Appeal to deliver food aid to thousands of displaced civilians as part of initial response in Lebanon
- BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
- BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
- Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
- Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results
- Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
- BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
- New partnership to fast-track Canadian health technology from innovation to patient care
- Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions
- Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions
- New partnership to fast-track Canadian health technology from innovation to patient care
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News